Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Receivables (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Receivables for 6 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 57.55% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 57.55% year-over-year, with the annual reading at $3.2 million for FY2025, 57.55% down from the prior year.
  • Receivables hit $3.2 million in Q4 2025 for Rapid Micro Biosystems, down from $5.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $7.6 million in Q4 2024 to a low of $3.2 million in Q4 2025.
  • Historically, Receivables has averaged $5.0 million across 5 years, with a median of $5.0 million in 2024.
  • Biggest five-year swings in Receivables: soared 43.0% in 2023 and later plummeted 57.55% in 2025.
  • Year by year, Receivables stood at $5.4 million in 2021, then increased by 1.26% to $5.5 million in 2022, then grew by 2.98% to $5.6 million in 2023, then skyrocketed by 35.28% to $7.6 million in 2024, then tumbled by 57.55% to $3.2 million in 2025.
  • Business Quant data shows Receivables for RPID at $3.2 million in Q4 2025, $5.5 million in Q3 2025, and $6.1 million in Q2 2025.